An Interferon-Free, Ribavirin-Free 12-Week Regimen of Daclatasvir, Asunaprevir, and BMS-791325 Achieved High SVR4 Rates

January 2013
Gastroenterology & Hepatology;Jan2013 Supplement, p17
Academic Journal
The article presents a study which examines the peginterferon-free, ribavirin-free regimen of declatasvir, asunaprevir, and BMS-791325. The 32 genotype 1 hepatitis C virus (HCV) infected patients were given asunaprevir, declatasvir, and BMS-791325 for 24 weeks in group one and 12 weeks in group two. According to the interim data of the 2012 American Association for the Study of Lung Diseases (AASLD) meeting, the 12-week therapy with the three direct-acting antiviral agents was well tolerated.


Related Articles

  • A 12-Week Interferon-Free Treatment Regimen with ABT-450/r, ABT-267, ABT-333, and Ribavirin Achieves High SVR12 Rates.  // Gastroenterology & Hepatology;Jan2013 Supplement, p11 

    The article presents a study on the administration of ritonavir-boosted human immune virus (HIV) protease inhibitors among healthy volunteers. It states that the study has three clinical trials including the phase II hepatitis C virus (HCV)/(HIV) co infection study, the phase III sprint-2 study,...

  • Commentary.  // Gastroenterology & Hepatology;Jan2013 Supplement, p18 

    The author discusses some of the studies presented at the 2012 American Association for the Study of Lung Diseases (AASLD) meeting which focuses on the management of hepatitis C virus (HCV) infection. He mentions the Anemia Management Study which examines the impact of timing and magnitude of...

  • High Rate of SVR with the All-Oral Combination of Daclatasvir Plus Sofosbuvir with or without Ribavirin.  // Gastroenterology & Hepatology;Jan2013 Supplement, p16 

    The article presents a study on the introduction of oral agents which can effectively cure hepatitis C virus (HCV) infection. It says that direct-acting antiviral agents that can be taken orally includes the NS5A replication complex inhibitor declatasvir and the nucleotide analogue NS5B...

  • News From the Liver Meeting. Lichtenstein, Gary R. // Gastroenterology & Hepatology;Dec2014, Vol. 10 Issue 12, p763 

    An introduction is presented in which the editor discusses the 2014 Liver Meeting held in Boston, Massachusetts on November 7-11 and articles within the issue including an interview with Dr. Nezam H. Afdhal on the ION trials, hepatitis B virus-HIV coinfection and the evaluation of data for the...

  • THE NEXT WAVE OF HCV CARE: ALL-ORAL TREATMENT STRATEGIES. Sulkowski, Mark // Johns Hopkins Advanced Studies in Medicine;Jun2014, Vol. 14 Issue 1, p16 

    Recently approved direct-acting antiviral agents (DAAs) are recommended for use in combination with peginterferon (PEG) for interferon (IFN)-eligible patients. PEG is associated with significant adverse events, and many patients are not eligible for PEG therapy due to comorbid conditions or...

  • Riociguat effectively treats chronic pulmonary hypertension. Lyon, Sue // British Journal of Hospital Medicine (17508460);Dec2012, Vol. 73 Issue 12, p671 

    The article reports a study which revealed that the investigational drug riociguat significantly improves markers for better outcomes in patients with inoperable or residual chronic thromboembolic pulmonary hypertension. The drug also resulted in significant improvements in secondary end points,...

  • Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors. Dunbar, E.; Coats, B.; Shroads, A.; Langaee, T.; Lew, A.; Forder, J.; Shuster, J.; Wagner, D.; Stacpoole, P. // Investigational New Drugs;Jun2014, Vol. 32 Issue 3, p452 

    Background Recurrent malignant brain tumors (RMBTs) carry a poor prognosis. Dichloroacetate (DCA) activates mitochondrial oxidative metabolism and has shown activity against several human cancers. Design We conducted an open-label study of oral DCA in 15 adults with recurrent WHO grade III - IV...

  • Sweetgrass asked.  // Alberta Sweetgrass;May2002, Vol. 9 Issue 6, p9 

    Focuses on the lessons learned by the participants during the conference on hepatitis C in Alberta. Accounts on the ways of transmitting hepatitis C virus; Susceptibility of Aboriginal people to the disease.

  • Hepatitis C. Klotter, Jule // Townsend Letter for Doctors & Patients;Dec2002, Issue 233, p22 

    Highlights the second National Institutes of Health Consensus Conference on the Management and Treatment of Hepatitis C in the U.S. on June 2002. Modes of hepatitis C virus transmission; Effect of blood screening prior to transfusion on the spread of the virus; Symptoms of acute hepatitis.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics